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Abstract 
The extracellular matrix (ECM) provides dynamic biochemical and structural cues that 
control cell proliferation, signalling, and homeostasis.  A critical feature of the ECM is its 
cryptic sites, hidden biologically active sites exposed through structural alteration or 
proteolytic cleavage events.  In this project, a cryptic signalling fragment derived from the 
laminin-111 protein is explored as a potential control switch for the epithelial-to-
mesenchymal transition (EMT), a critical process in development, wound healing, and 
cancer progression.  One EMT-related pathology in wound healing is fibrosis, the 
accumulation of excess scar tissue that inhibits normal tissue function.  A potential strategy 
in treating this disease is to control or slow the EMT process during wound healing to 
prevent epithelial cells from transforming into myofibroblasts that contribute to fibrotic tissue.  
The effect of the cryptic fragment is characterised in Mus musculus mammary gland 
epithelial cells (NMuMGs) undergoing transforming growth factor β (TGFβ) induced EMT 
using imaging, biochemical, and molecular-biological techniques.  The fragment is then used 
to engineer a biomimetic basement membrane (BM), using polydopamine coated poly(ε-
caprolactone) as the structural scaffold.  This system allows stable binding of proteins, as 
well as providing a suitable surface for epithelial cell proliferation.  In this work it is shown 
that the cryptic fragment directly down-regulates crucial EMT genes in this artificial BM 
system in NMuMGs, providing a potential reduction of fibrosis pathology.  Future and 
ongoing work will continue to optimise the system and lead to other applications of EMT 
control both for in vivo and in vitro studies.  This project explores the still widely unused 
potential of cryptic ECM information in tissue engineering. 
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1. Introduction 
1.1 The Extracellular Matrix and Cryptic Sites 
The extracellular matrix (ECM) is the assortment of proteins that surround the outside of 
cells and define their environment.  Critical signalling in all stages of a cell’s life involves the 
interaction of cellular membrane proteins such as integrins with elements from the ECM.1  
The properties of the ECM are defined by its proteins, soluble growth factors, topology, 
stiffness, assembly, and dynamics.  As such, the composition of the ECM proteins in both 
type and abundance varies greatly in different regions of the body, allowing highly specific 
properties. An example of this phenomenon is the specialised ECM in bone, which consists 
mostly of type I collagen that imparts stiffness and structural integrity.2  The ECM is also 
responsive to cells, which can affect the properties of the ECM in response to changing 
conditions.  One aspect of the ECM that lends to its dynamic role is the presence of cryptic 
sites, hidden signalling “switches” located in certain ECM proteins that are activated by a 
specific event that can originate from the cell or the environment.3  A triggering event such 
as the release of proteases or a conformational shift allows for the specific processing of 
proteins and exposing of cryptic sites.  This action alters cell signalling and allows the cell to 
give a dynamic response related to the circumstances that triggered activation.  There are 
several examples of cryptic sites that have been discovered in ECM proteins fibronectin, 
laminin-111, and collagens IV, XV, XVIII.3,4   In many cases, a cellular enzyme cleaves a 
sequence or structure-specific protein component of the ECM, which leads to the release of 
protein fragments or an alteration of protein conformation, revealing hidden sites that give 
rise to novel cell-ECM interactions.5 
1.2 Laminin – A crucial protein of the ECM with Cryptic Sites 
Laminin is a key protein in the ECM, particularly in the basement membranes (BM), cell-
associated ECMs that cover the basal side of epithelial and endothelial cells.  Basement 
membranes are composed mostly of laminins, type IV collagens, nidogens, fibronectin, and 
numerous proteoglycans, along with macromolecules including growth factors.6,7  The 
laminin proteins are composed of three subunits, one of each of the α, β, and γ chains, with 
the nomenclature of each chain referring to its different chain isomers (e.g. laminin - 511).8  
Its polymerisation is mediated by Laminin N-terminal (LN) domains at the termini of the three 
short arms of the heterotrimer that allows stable association with other laminin arms into a 
mesh-like network in the presence of calcium.9  The Laminin Globular (LG) domains of α 
chains and some Laminin-type Epidermal Growth Factor-like (LE) modules bind to perlecan, 
heparin, agrin, and nidogen, which bridges laminin to type IV collagen.10  The laminin-
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collagen network thus forms the core integral BM structure.11,12  Laminins exhibit dynamic 
behaviour, and have the ability to self-assemble and bind macromolecules.  They bind to 
cellular receptors mainly through integrins and dystroglycans, playing a large role in 
establishing epithelial polarity and development.13  Distinct laminin domains have been 
shown to be biologically active and harbour cryptic sites, including specific LN domains, 
nidogen-binding sites, and cell-binding sites.14  Different laminin isoforms are present 
depending on the tissue but all play several important roles in tissue morphogenesis, such 
as organising cellular tissues and protecting adherent cells.15  One particular isoform, 
laminin-111, plays a critical role as the most abundant laminin during embryonic 
development, supporting a variety of functions including neurite outgrowth, cellular migration, 
and receptor clustering.7   
In Molly Stevens’s group at Imperial College, a previously unidentified cryptic fragment of 
laminin-111 has been shown to modulate the epithelial to mesenchymal transition (EMT) in 
mouse and human embryonic stem cells (mESCs and hESCs).  This work demonstrates the 
still widely unknown potential of cryptic ECM sites that play a crucial role in cell 
differentiation.  In allowing embryonic stem cells (ESCs) to differentiate both in monolayer 
culture and as embryoid bodies that mimic post-implantation embryonic tissue, ESCs 
undergo transformations that are significantly affected in the presence of the laminin cryptic 
fragment.  Using mESCs and hESCs, this fragment appears to have properties that can alter 
the EMT, the cell differentiation process that provides the basis for development.16,17  
1.3 Overview of the Epithelial-to-Mesenchymal Transition 
The EMT is responsible for the formation of most adult tissues and organs.  Cells of an 
epithelial type are phenotypically characterised by close contacts with each other, a firmly 
established axis of polarity.  Precise arrangement of adherens junctions, desmosomes, gap 
junctions, and tight junctions mediate firm attachment to adjacent cells and maintenance of 
polarity.18  These cells are prevalent throughout the body and exist in most organ systems.  
Conversely, cells of a mesenchymal phenotype are loosely organised with no polarity or tight 
junctions, which enables them to migrate.  The conversion from epithelial cells involves the 
loss of cell-cell adhesion, polarity, and acquiring the ability to migrate.  This transformation 
can be visualised as a dramatic remodelling of actin filaments and cell morphology, with a 
degradation of attachment proteins in the ECM.19  The EMT is characterised genotypically by 
increased expression and activity of Slug and Snail transcription factors, increased matrix 
metalloproteinase (MMP) activity, vimentin expression and especially a decrease in E-
cadherin expression and up-regulated N-cadherin expression, a process known as cadherin 
switching that plays a role in destabilizing the actin cytoskeletal arrangement.17,20,21  The 
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process of EMT is crucial in early development, where cells attached to the early basement 
membrane need to detach and migrate to specific regions and differentiate into specific 
tissues.  Evidence of EMT in the adult tissue occur in wound healing, where epithelial cells 
migrate from areas surrounding a wound to fill a cavity, and in cancer metastasis, where 
certain malignant tumour cells migrate from the primary tumour to establish a secondary 
tumour in a different area of the body.22 
The proteolytic processing of proteins of the extracellular basement membrane during EMT 
is facilitated by MMPs.  MMPs are cellular enzymes (zinc endopeptidases) that cleave a 
variety of proteins, usually by sequence-specific recognition.  The set of MMPs produced by 
humans can cleave virtually any protein in the ECM, with both secreted and membrane-
bound MMPs produced by the cell.23,24  The role of MMPs in a variety of EMT processes is 
evident, including development, wound healing, and cancer.4,24  In all of these processes, 
cells require MMPs to cleave the ECM to facilitate detachment and migration.  MMPs have 
been the target of multiple drug inhibitors for cancer and fibrosis pathologies, largely with 
disappointing results.25  The cause of these failures is likely being the large role MMPs play 
in all crucial processes, with complete inhibition of MMP activity a fatal event for many cells. 
1.4 How a laminin-111 cryptic site affects the EMT 
A cryptic site of laminin-111 is revealed specifically by MMP2, whose expression is highly 
up-regulated during EMT.16  MMP2 (also known as gelatinase A), has been shown to 
degrade certain types of collagen (IV, V, VII, X), laminins, fibronectin, elastin, and 
contributes to the activation of other MMPs secreted by the cell.24  MMP2 cleavage releases 
a fragment from the N-terminal part of the β1-chain containing LN and LE domains (Ln-Le1-
4), which was identified using peptide fingerprinting with liquid-chromatography tandem 
mass spectrometry (LC-MS) (Figure 1A).16  Cleavage of this domain by MMP2, which is up-
regulated during EMT and embryonic differentiation, releases the fragment from the 
basement membrane and allows it to act as a signalling peptide (Figure 1B, C).  Laminin-111 
interacts with the α3β1 isoform of integrin receptors, which is responsible for cytoskeleton 
assembly, facilitating cell migration, cell-cell junctions, and also regulates MMPs through the 
EMMPRIN protein (Figure 1E).26-28 Using laminin as both a soluble factor in solution and an 
immobilised factor on the surface of a tissue culture plastic (TCP), mouse and human ESCs 
were observed to have EMT genes significantly altered – there is evidence of E-cadherin up-
regulation, slug and snail down-regulation, and MMP2 down-regulation (Figure 1D).  Thus, 
the cryptic laminin fragment appears to initiate a negative-feedback mechanism using MMP2 
to slow down the EMT process once the basement membrane has been affected to a certain 
point.  As EMT is occurring in development, MMP2 cleaves the basement membrane to 
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release the fragment, and once enough fragment has been released it will signal to the cell 
via integrins to start to inhibit expression of EMT genes.  Pathway studies involving an 
EMMPRIN-blocking antibody fully block the laminin fragment EMT influence, further 
supporting its binding and signalling pathway through MMP2 and integrin α3β1 (Figure 1F).  
Establishing this link between MMP-ECM interactions opens up new possibilities to engineer 
bioactive materials that use this novel control switch. 
1.5  Fibrosis and the EMT – The Implication of MMPs 
Fibrosis is one of the main pathologies involving both the ECM and the EMT.  It is a 
detrimental condition in wound healing marked by the deposition of scar tissue after severe 
injury, often compromising organ function.29  In functional homeostasis of many tissue 
systems, ECM turnover is regulated by MMPs and tissue inhibitors of metalloproteinases or 
TIMPS.23  In fibrosis, epithelial cells, macrophages, T-cells and fibroblasts become activated 
and can either be recruited or differentiate into a fibroblast-like phenotype that is highly 
related to the expression and activity of multiple MMPs and TIMPs.30  Degradation of the 
ECM by MMPs can lead to the release of ECM-bound cytokines such as TGF-β that can 
induce fibrogenesis.23  In fibrotic tissues, fibroblasts display characteristics of myofibroblasts, 
which secrete excessive fibrous proteins, mainly composed of collagen type I.  Studies have 
shown that these myofibroblasts are involved in a multitude of diseases, including cardiac 
and liver fibrosis, and that they can be derived from epithelial or endothelial cells; in the case 
of cardiac fibrosis, vascular endothelial cells undergo a specialised endothelial-to-
mesenchymal transition (EndoMT) that is phenotypically similar to normal EMT.31-33  
EMT/EndoMT promotes the progression of the pathology by generating new cells of 
mesenchymal phenotype that can become myofibroblasts, as well as causing tissues to lose 
healthy epithelial cells.  Lens epithelium, endothelium, hepatocytes, and cardiomyocytes can 
all undergo EMT and transform into fibrotic tissue.18  Thus, a possible pathway to target 
fibrosis is to establish the regulatory systems of myofibroblasts and their pro-fibrotic 
behaviour.34  
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Figure 1 | The Laminin Cryptic Site 
A, MMP2 activity assay for mouse (top) and human (bottom) embryonic stem cells (ESCs) on various 
days of differentiation in comparison to pluripotent cells. B, Native and denatured SDS-PAGE 
Coomassie blue-stained laminin-111.  Lane 1: Molecular mass standard (MMS); Lane 2: Whole 
laminin-111 (too large to enter gel); Lane 3: Laminin-111 digested with MMP2; Lane 4: MMS; Lane 5: 
Denatured laminin-111 processed with MMP2.  Top two bands correspond to the α, β, and γ chains 
with no processing, while a ~60 kDa fragment is present that is identified as the cryptic fragment Ln-
Le1-4.  C, Schematic of laminin-111 – the red segment shows the identified cryptic fragment.  D, Cell 
attachment to Ln-Le1-4 was identified by blocking specific receptors using anti-integrin subunit 
antibodies and the binding is then quantified by crystal violet staining.  Data is relative to non-blocked 
cells.  E, qPCR relative EMT gene expression levels showing the influence of the laminin fragment.  
The fragment was administered both as a soluble factor in solution and as an immobilised peptide on 
the surface of a tissue culture plastic (both in monolayer culture).  F, Use of an anti-EMMPRIN 
antibody blocks the effect of the fragment regarding gene expression by q-PCR in mouse ESCs.  All 
significance in figures calculated as P < 0.05.  All images adapted from Horejs et al. (Reference 16). 
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MMP2 and MMP14 up-regulation in particular is associated with progression of mild fibrosis 
to liver cirrhosis.35 In previous studies, treatment with proteins interleukin-10 or interferon-α 
and γ reduced TIMP-1 and MMP2 levels while reducing fibrosis in rat models.36,37  Due to the 
strong relationship between MMPs and the ECM, MMP inhibitors have been widely explored 
as a way of curbing excessive ECM proteolysis in a variety of pathologies.30,38  Most of these 
therapies involve small molecules and were unable to translate into clinical application due 
to the side effects of systematically inhibiting MMP activity and due to issues with 
administered doses, as MMP activity is necessary for many pro-survival cellular 
processes.25,39  There have been efforts to inhibit other parts of the EMT in cancer therapies, 
but due to the involvement of EMT in many pathways, the problem of non-specificity still 
arises.40  As a result, recent studies have focused on local delivery of MMP inhibitors, such 
as through injectable hydrogels that release TIMPs.41  One of the weaknesses, however, is 
the non-specificity of TIMPs, as they inhibit multiple MMPs.  During the progression of 
wound healing related fibrosis, some EMT is required for normal repair and ECM turnover, 
and thus drastically decreasing MMP activity is not as desirable as moderately down-
regulating it so that fibrotic scarring is reduced.   
1.6 Tissue Engineering Materials 
The field of tissue engineering for wound healing has seen marked progress in recent years.  
With the ever-expanding understanding of the crucial interplay between cells and their 
environment, much recent effort has been dedicated to creating an ECM environment in vitro 
that allows optimal regeneration of new tissue by delivering the correct structural guidance 
and bioactive cues.42  One way to emulate signals from the ECM is to use specific small 
peptides that can be linked to scaffolds to provide cells with both mechanical support 
through the scaffold and growth signalling through the peptide.43  Efforts have been made 
before to recreate synthetic matrices that are more tunable and consistently high quality.44  
However, such approaches involve complex protein conjugation methods such as chemical 
crosslinking, surface etching, or plasma treatment that may degrade larger peptides.45  
Besides the problems with protein conjugation, the base scaffold itself must also be 
consistently reproducible, high quality, and biodegradable.  A promising avenue in creating 
artificial polymer materials with tunable properties is through electrospinning, which allows 
for the creation of fibrous scaffolds that can mimic the physical architecture of the ECM.  
These electro-spun fibres can be varied in diameter, alignment, and density to model both 
the topology of the ECM and its mechanical properties and are thus suitable to produce a 
biomimetic system that can be adapted to a variety of ECMs in different tissues.  In 
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particular, Poly(ε-caprolactone) (PCL) fibre mats appear to fit the purpose of such a 
biomimetic scaffold base, as it can also be mixed with other polymers to vary its mechanical 
properties as well as being readily biodegradable.46,47 Poly(ε-caprolactone) (PCL) electro-
spun fibres have been shown to be conducive to cell growth on the surface and readily 
mimic an articular cartilage ECM (Figure 2A, B).48  Thus, while there have been major 
advances in producing high quality scaffolds, there is still the challenge of how to effectively 
conjugate proteins to the surface in a way that does not denature or inhibit their bioactive 
properties. 
1.7 Polydopamine – A Method for Effective Protein Conjugation 
There has been much research in the development of functionalised biomimetic biomaterials 
that allow more sophisticated control of cell signalling and fate in vitro using signalling 
peptides, preferably without destructive chemical conjugations or inconsistent adsorption 
techniques.43,44  One novel approach to creating these biomimetic materials is to use 
polydopamine (pDA), a material inspired by mussel adhesive pads.49  L-dopamine is readily 
polymerised in alkaline conditions through reaction of its catechol groups to quinone in 
oxygen (Figure 2C).  The resultant polymer can then be coated onto substrates in a thin 
layer.49  These coatings show affinity for bioactive molecules that contain amine, thiol, or 
imidazole groups, thus presenting a wide variety of possible materials that can be bound to 
the surface.50 Studies have shown that peptide and antibody immobilisation are possible on 
pDA surfaces.43,51  Additionally, cells show increased adhesion on pDA alone with no 
detectable cytotoxicity, and are responsive to immobilised growth factors on the surface.52,53  
Polydopamine treated PCL scaffolds have already been shown to be a feasible system for 
cellular growth.54 Thus, combining an electro-spun PCL biomimetic ECM coated with pDA 
would be an extremely modular and reliable biomimetic system that allows for the possibility 
of a complete and accurate artificial basement membrane for regenerative applications 
(figure 2D).  A potential drawback of using pDA is the non-specificity of protein binding.  As 
such, precaution must be used to expose the pDA surface only to desired proteins and that it 
be fully saturated.  It appears that the long term binding stability of pDA to various peptides 
is not well characterised, and it may be that conditions such as forceful washing or constant 
fluid flow over the surface can displace previously-coated peptides over time. 
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Figure 2 | Poly(ε-caprolactone) and Polydopamine Functionalisation 
A, Chemical structure of Poly(ε-caprolactone) (PCL), a biodegradable polymer.  B, PCL fibers can be 
spun together to model an artificial extracellular matrix environment in random-alignment shown in 
this scanning electron microscope (SEM) image.  Scale bar = 10μm C, Dopamine is used by mussels 
as an adhesion technique.  It can be polymerised via oxidation and coated on a surface to allow facile 
functionalisation of peptides without chemical conjugation methods.  D, An artificial basement 
membrane system can be created using PCL coated polydopamine (pDA).  Electrospun poly(ε-
caprolactone) is punched from a sheet into small circular mats that are then exposed to a solution of 
polydopamine.  Laminin and collagen are coated on the surface and epithelial cells are then seeded.  
(B) courtesy of Dr. Jean-Philippe St.-Pierre. 
 
1.8 Engineering a Wound Healing Material that Controls Fibrosis 
The goal of this thesis project is to create a biomimetic material that can actively impact the 
EMT process of epithelial cells and thus provide a novel approach to target tissue fibrosis.  A 
targeted method using β1LnLe1-4 fragment on PCL coated with polydopamine provides a 
promising system.  This system differs from traditional scaffold functionalisation that seeks to 
maximise cell growth, and instead seeks to control fibrotic accumulation by down-regulating 
critical EMT genes while still providing strong cell attachment and viability.  Recombinant 
 
 
15 
 
laminin fragment can be produced and seeded onto the PCL pDA mats.55  Epithelial cells are 
then seeded onto this artificial basement membrane and made to undergo EMT.  TGFβ will 
be used to induce EMT in mouse epithelial cells through binding to Tsk7L type I receptors.56  
Sustained up-regulation of  TGFβ is implicated during inflammation that precedes fibrosis 
and cancer progression, and is therefore a relevant activator of EMT.57  TGFβ works through 
several pathways, including through Smad complexes, PI3K, ERK, and mTOR, and thus can 
reliably induce EMT in a wide variety of conditions.34,58 
This project has three milestones: 
1. Establishing the role of β1LnLe1-4 in EMT, first in mESCs and then in mouse 
epithelial cells. 
2. Optimizing and characterising a material system that allows use of the fragment to 
control the EMT. 
3. Characterising the role of β1LnLe1-4 on the EMT on the PCL pDA material using a 
variety of imaging, biochemical, and molecular biological techniques. 
1.9 Statement of Work: 
In the first part of my work as co-author on the paper: Biologically-active laminin-111 
fragment that modulates the epithelial-to-mesenchymal transition in embryonic stem cells, I 
was involved in characterising the effect of the laminin fragment on murine ESCs in 
monolayer culture and as embryoid bodies.16  Additionally, I prepared quantitative PCR 
(qPCR) experiments to determine change in protein expression due to blocking of 
extracellular matrix metalloproteinase inducer (EMMPRIN).  As the data was collected for 
the purposes of the previously published work, it will not be mentioned other than in the 
introduction, and the data and discussion presented in the main section will comprise solely 
of the mouse epithelial cell system and its characterisation regarding EMT, fragment 
influence, and on the PCL scaffold.  I was involved in planning, running, and analysing all 
experiments involving the mouse epithelial cells with the exception of confocal and TIRF 
images on PCL mats, in which I prepared the samples, and the imaging was done by 
Thomas von Erlach and Christine-Maria Horejs.  The PCL mat was electrospun with the help 
of Jean-Philippe St.-Pierre.  All images not credited to someone else were self-made. 
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2.       Results 
2.1 Characterisation of Response of Epithelial Cells to Cryptic Laminin 
Fragment 
2.1.1 Imaging Characterisation 
The model system uses a specific type of mouse epithelial cells, the NMuMG line derived 
from mammary glands.  In order to ascertain the effect of the laminin fragment on epithelial 
cell morphology during EMT, light and immunofluorescence microscopy was used.  To 
induce EMT, both TGFβ3 and TGFβ1 were initially used to determine if initializing EMT 
through slightly different pathways would change the effect of the laminin fragment or vary 
EMT phenotype significantly.  Figure 3 shows light microscopy images for both TGFβ3 and 
TGFβ1 induced EMT in NMuMG cells.  Laminin fragment was added as a soluble factor 
before the induction of EMT.  There is a dramatic change in morphology upon the addition of 
TGFβ3 and TGFβ1 after 24 hrs, but the fragment does not appear to significantly change the 
overall morphology. 
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Figure 3 | Light Microscopy of NMuMG cells 
A, Experiment with EMT induced via TGFβ3 for 24 hrs. (i) control; (ii) β1LnLe1-4; (iii) TGFβ3; (iv) 
β1LnLe1-4 and TGFβ3. Scale bar = 100μm.  B, Experiment with EMT induced via TGFβ1 for 24 hrs. 
(i) control; (ii) β1LnLe1-4; (iii) TGFβ1; (iv) β1LnLe1-4 and TGFβ1. Scale bar = 200μm.  
For immunostaining, time dependent fragment influence was also studied, as well as any 
potential differences between TGFβ3 and TGFβ1 (Figures 4-7).  For TGFβ3, cells had EMT 
induced for 24 hrs or 48 hrs and were then fixed and stained for EMT-related proteins: E-
Cadherin, N-Cadherin, Fibronectin, and Actin.  For TGFβ1, cells had EMT induced for 48 hrs 
and were fixed and stained for EMT-related proteins: E-Cadherin, N-Cadherin, Fibronectin, 
and Collagen I.  Immunostaining imaging for TGFβ1 induction at 24 hrs was not done after 
comparison of 48 hr results with TGFβ3 showed no qualitative difference, as it is likely that 
there would be no discernible differences at shorter stimulation times.  Image results show 
that laminin fragment addition appears to have a qualitative effect on Collagen I, with treated 
samples showing reduced staining intensity.  Fibronectin also appears to be qualitatively 
slightly different. 
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Figure 4 | Immunostaining of NMuMG Cells with TGFβ3 EMT Induction for 24 hrs 
Representative images from fixed cells after 24 hrs of adding TGFβ3 and staining with antibodies for 
A, Anti-E-Cadherin, N-Cadherin and B, Anti-Fibronectin, and Actin.  Some contrast and sharpening 
adjustments were made.  Scale bar = 100μm. 
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Figure 5 | Immunostaining of NMuMG Cells with TGFβ3 EMT Induction for 48 hrs 
Representative images from fixed cells after 48 hrs of adding TGFβ3 and staining with antibodies for 
A, Anti-E-Cadherin, N-Cadherin and B, Anti-Fibronectin, and Actin.  Some contrast and sharpening 
adjustments were made.  Scale bar = 100μm. 
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Figure 6 | Immunostaining of NMuMG Cells with TGFβ1 EMT Induction for 48 hrs 
Representative images from fixed cells after 48 hrs of adding TGFβ1 and staining with antibodies for 
A, Anti-E-Cadherin, N-Cadherin and B, Anti-Fibronectin, and Collagen type I.  For E-cadherin, N-
cadherin, and collagen type I some contrast adjustment was made. Some contrast and sharpening 
adjustments were made.  Scale bar = 100μm. 
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From the microscopy images we were able to determine that the fragment did not 
morphologically alter NMuMG cells significantly both in control and TGF-induced EMT.  
Additionally, TGFβ1 and TGFβ3 pathways were not significantly different, in that the cells 
undergo the same EMT phenotypic changes using either growth factor for both 24 and 48 hr 
time periods.  These results were encouraging as it is undesirable for the fragment to 
interfere completely with the EMT process, as was the case with certain inhibitor drugs.40  In 
wound healing, the critical EMT process must continue, but not progress to fibrosis.  There 
was not qualitative evidence of cadherin switching, as problematic staining with the cadherin 
antibodies led to inconsistent imaging across samples.  Reasons may include over-
permeabilisation or poor antibody specificity due to the antibodies being raised against 
human proteins (though all were supposedly also successfully tested with mouse proteins). 
Evidence from previous literature where NMuMGs are stimulated with TGFβ1 or TGFβ3, 
however, suggests that the phenomenon can be visualised.59,60 
2.1.2 Protein Expression Analysis 
To characterise the change in expression of critical EMT genes, western blot and qPCR 
were used.  In western blot analysis, presence of EMT-critical gene products E-Cadherin, N-
Cadherin, and Fibronectin were successfully identified, though Collagen type I and 
EMMPRIN antibodies did not appear to work, possibly due to the denaturing process of 
preparing samples.  Figure 7 shows that both E and N-Cadherin proteins were expressed, 
but EMT E/N-Cadherin switching is not entirely clear.  Fibronectin appears to show a clear 
increase under EMT induction, especially when considering relative to GAPDH bands.  EMT 
induction time was also tested, varying between 24 hrs and 4 days. 
 
Figure 7 | Western Blot of EMT proteins 
A, Anti - GAPDH, E-Cadherin, and N-Cadherin antibodies identify presence of critical EMT genes in 
NMuMG cells after inducing EMT for 24 hrs.  Lane 1: Control NMuMG; Lane 2: β1LnLe1-4 fragment 
added; Lane 3: TGFβ3-induced EMT; Lane 4: β1LnLe1-4 and TGFβ3 EMT.  B, GAPDH and 
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Fibronectin western blot in separate experiment looking at time-dependent EMT induction shows 
increase of fibronectin.  Lane 1: Control; Lane 2: β1LnLe1-4 fragment; Lane 3: TGFβ3 for 24 hrs; 
Lane 4: β1LnLe1-4 fragment and TGFβ3 for 24 hrs; Lane 5: TGFβ3 for 48 hrs; Lane 6: β1LnLe1-4 
fragment and TGFβ3 for 48 hrs; Lane 7: TGFβ3 for 4 days; Lane 7: β1LnLe1-4 fragment and TGFβ3 
for 4 days. 
The western blots showed that EMT-critical proteins were being expressed and expression 
was varying in response to EMT induction via TGFβ.  To provide a more quantitative and 
sensitive evaluation of fragment influence and EMT signaling, qPCRs were performed.  In 
the first set of qPCR experiments, TGFβ3 was added and EMT induced for 24 hrs, with the 
medium complemented with 10μM laminin fragment.  Results in Figure 8 show that there is 
clear evidence of EMT events, notably down-regulation of E-cadherin, up-regulation of 
MMP2, collagen type I, and fibronectin.  These effects show that the morphological change 
of NMuMGs is accompanied by changes in mRNA expression.  
 
 
Figure 8 | qPCR for NMuMG with Soluble Laminin Fragment 
EMT-related gene expression levels in terms of fold change relative to control non-EMT NMuMG 
cells.  1st bar (blue): β1LnLe1-4 only; 2nd bar (red): TGFβ EMT; 3rd bar (green): β1LnLe1-4 and TGFβ 
EMT.  Log(Fold Change) > 0 indicates up-regulation while negative values indicate down-regulation.  
*P < 0.05 EMT conditions compared to non-EMT conditions.  Error bars show standard error of mean 
(SEM) of replicates. For all genes N = 3. 
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To further characterise NMuMG genetic changes due to EMT, a time-dependent study was 
performed for 1 day, 2 days, and 4 days of inducing EMT via TGFβ3.  Figure 9 shows that 
there is roughly a correspondence between days of EMT induced and the fold change in 
mRNA expression of certain genes.  Here it appears that there are some changes caused by 
fragment influence, but unfortunately due to the high variability no statistical significance can 
be gained.  Overall, however, there is a trend for MMP2 and collagen type I being affected 
by the presence of the laminin fragment.  In order to enhance laminin fragment contact with 
NMuMG cells, the fragment was pre-adsorbed to the bottom of tissue culture plastic instead 
of added as a soluble factor.  TGFβ1 was then added to induce EMT.  Cells were treated 
with medium complemented with TGFβ1 for 2 hrs, 5 hrs, 24 hrs, and 4 days.  Figure 10 
shows that there are no EMT-characteristic gene-expression changes until TGFβ treatment 
for 5 and 24 hrs, while after 4 days the cells become overly confluent.  Overall, this initial 
characterisation of NMuMG cells builds a foundation upon what is to be expected in the 
material system in terms of EMT gene expression level changes and possible fragment 
influence.  Based on the most consistent results being from the 24 hr time point, all future 
EMT experiments had TGFβ1 added 24 hrs before sample characterization. 
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Figure 9 | qPCR for NMuMG with Soluble Laminin Fragment with Varying Times 
EMT-related gene expression levels in terms of fold change relative to control non-EMT NMuMG 
cells. EMT was induced by adding TGFβ and waiting for either 1 day, 2 days, or 4 days, with the 
control cells harvested at the same time as the 2-day samples.  1st bar (blue): β1LnLe1-4 Only 
Control; 2nd bar (red): 1-Day TGFβ EMT; 3rd bar (green): 1-Day β1LnLe1-4 and TGFβ EMT; 4th bar 
(purple): 2-Day TGFβ EMT; 5th bar (orange): 2-Day β1LnLe1-4 and TGFβ EMT; 6th bar (black): 4-Day 
TGFβ EMT; 7th bar (brown): 4-Day β1LnLe1-4 and TGFβ EMT.  Log(Fold Change) > 0 indicates up-
regulation while negative values indicate down-regulation.  *P < 0.05 EMT conditions compared to 
non-EMT conditions.  The horizontal line indicates that every sample under the line is significant to 
the other indicator.  Error bars show SEM of replicates.  For E, N-Cadherin, MMP2 N = 2.  For all 
other genes N = 1. 
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Figure 10 | qPCR for NMuMG with TCP-Adsorbed Laminin Fragment with Varying Times 
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EMT-related gene expression levels in terms of fold change relative to control 2-day non-EMT 
NMuMG cells for A) 2 hrs, B) 5 hrs, C) 24 hrs, D) 4 days after TGFβ1 addition. 1st bar (blue): 
β1LnLe1-4 Control; 2nd bar (red): TGFβ EMT; 3rd bar (green): β1LnLe1-4 and TGFβ EMT (all 
samples). *P < 0.05 EMT compared to non-EMT conditions.  Error bars show SEM of replicates.  For 
2 hr genes, N = 1, for 5 hr genes N = 2, for 24 hr genes E, N-cadherin, MMP2, EMMPRIN, Fibronectin 
N = 3, and everything else N = 2, for 4 day genes N = 1. 
 
2.2 Designing a Biomimetic Cryptic Basement Membrane System  
2.2.1 Protein Binding Characterisation 
In order to determine the optimal protein concentrations, incubation medium, and adsorption 
time, a preliminary characterisation of binding on pDA-coated PCL mats was performed.  
Collagen type I dissolved in acetic acid is diluted to 100µg/mL with either PBS or 10mM Tris 
pH 8.5 and incubated with PCL with and without pDA coating.  To characterise protein 
binding, the antibody intensity of an anti-Collagen I antibody was measured using an infrared 
dye conjugated secondary antibody.  Signal was quantified using an infrared (IR) detector 
(Figure 11A, C, D).  Additionally, a BCA protein assay wacs performed, measuring the 
concentration of laminin-111 protein left in solution after PCL mats were incubated for 
varying periods from 5 min to 24 hrs as a proxy for protein adsorption onto the PCL mats 
(Figure 11B).  Results indicate that PBS and 10mM Tris show approximately equal binding 
efficiency, so PBS was used for all further experiments.  Interestingly, non-pDA coated PCL 
showed higher binding signal in the IR assay (Figure 11C).  In non-air plasma treated 
samples, PCL not-coated with pDA continued to show higher protein binding (Figure 11D).  
Ultimately, it appeared that comparison between the binding on non-coated and pDA-coated 
PCL mats using IR was rendered difficult by quenching of the signal by the pDA coating, 
possibly due to the aromatic groups in the coating.  Additionally, lower signal may also be a 
result of differences in changed surface properties that result in less nonspecific adsorption 
but tighter binding, due to interaction of pDA with thiol and amine groups through Michael 
addition or Schiff base reactions.61 Hence, even if there was a greater amount of protein in 
non pDA mats, it is still more desirable to coat with pDA to ensure even and stable protein 
coating. Thus, the indirect method of measuring the protein removal from the solution was a 
better approach to determine protein binding.  From the results of the BCA-binding assay, 
binding appeared to approach saturation around 6-8 hrs.  As such, in the optimised system 
protein is dissolved in PBS and coated for at least 8 hrs to reach theoretical saturation.   
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Figure 11 | Protein Binding Characterisation of Polydopamine Coated Poly(ε-caprolactone) 
Mats 
A, Anti-Collagen type I antibodies show that protein is successfully bound to PCL mats after several 
gentle washing steps.  Protein was dissolved in both PBS and Tris buffer to investigate their effect on 
binding. B, BCA protein assay shows amount of laminin-111 left in solution of pDA PCL mats over 
time. C, Quantification of IR absorbance signal from (A), normalised to dry mass of each PCL mat.  D, 
Comparison of non-pDA and pDA coated mats without treatment of plasma air (PA) for 24 hrs.  
Sample size N = 1, n = 3.  Error bars shown SEM of repeats. 
To directly visualise protein-binding on pDA PCL mats, FITC-labelled laminin fragment was 
coated on the mats and imaged using confocal imaging and total internal reflection 
fluorescence (TIRF) microscopy (Figure 12D).  The TIRF image indicates individual fragment 
presence.  Cells seeded on mats were also fixed and stained for confocal imaging.  A 
quantification of the fluorescence intensity signal normalised to a PBS only control shows 
that that fragment is stably bound, and increased concentration of fragment results in an 
increase in fluorescence intensity (Figure 12A-C)  
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Figure 12 | TIRF and Confocal Images of Labelled pDA PCL Mats 
A, Confocal images of PCL mats coated with FITC-labeled β1LnLe1-4 at concentrations of 
0.01mg/mL and 0.1mg/mL.  B, Control PBS only PCL mats for each experiment.  Scale bars = 150μm 
C, Fluorescence intensity quantification of (A) normalised to (B) samples shows significant intensity 
signal for labelled laminin fragment.  Error bars show SEM, n = 3. D, TIRF image of labelled fragment.  
Scale bar = 5μm.  Images by Thomas von Erlach. 
 
2.2.2 Characterisation of Effect of Biomimetic Material on Epithelial Cells 
To see if EMT gene expression is affected by the material, qPCRs were performed to assess 
NMuMG epithelial cells undergoing TGFβ-induced EMT (Figure 13).  Due to the small 
quantities of cells per sample, the heterogeneity of each condition gave high variation in 
genetic expression levels.  Over the course of several repeats the fold change could vary by 
several orders of magnitude for the same condition, due to the topology of the PCL mat, the 
passage number of the cells, and small variations in handling the system.  From combined 
repeats, MMP2, collagen I, and fibronectin expression during EMT with fragment appears to 
be down-regulated compared to the pDA PBS control, though multiple-hypothesis 
corrections do not cross P<0.05 when EMT conditions across different PCL pDA coatings 
are compared to the control condition (Figure 13B-D).  The fragment itself changes some 
expression levels even without EMT induction, as expected from its bioactivity.  Interestingly, 
in cells of epithelial phenotype on materials with only Collagen type IV coating, MMP2, 
Collagen I, and Fibronectin are all up-regulated, indicating bioactivity of Collagen IV on the 
PCL pDA mats without EMT induction. 
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Figure 13 | qPCR Results of Cells Seeded on Different Materials 
EMT-related gene expression levels in terms of fold change relative to control pDA PBS non-EMT 
NMuMG cells A) E-cadherin, B) MMP2, C) collagen type I, D) fibronectin for cells taken from PCL 
mats.  Each of the bars from left to right shows: 1 (blue): pDA PBS TGFβ EMT; 2 (red): pDA β1LnLe1-
4; 3 (green): pDA β1LnLe1-4 + TGFβ EMT; 4 (purple): pDA Collagen I; 5 (orange): pDA Collagen I + 
TGFβ EMT; 6 (black): pDA β1LnLe1-4 + Collagen I; 7 (brown): pDA β1LnLe1-4  + Collagen I + TGFβ 
EMT; 8 (dark blue): pDA Collagen IV; 9 (dark purple): pDA Collagen IV + TGFβ EMT; 10 (dark red): 
pDA β1LnLe1-4 + Collagen IV; 11 (dark green): pDA β1LnLe1-4 + Collagen IV + TGFβ EMT.  For E-
cadherin and MMP2 the further columns are 12 (light brown): Non-pDA PBS; 13 (light green) Non-
pDA PBS + TGFβ EMT; 14 (light blue): Non-pDA β1LnLe1-4; 15 (light purple): Non-pDA β1LnLe1-4 + 
TGFβ EMT. *P < 0.05 EMT compared to non-EMT of similar treated PCL mat.  Error bars show SEM 
of replicates.  For pDA PBS TGFβ EMT, pDA β1LnLe1-4, and pDA β1LnLe1-4 + TGFβ EMT N = 6.  
For pDA with Collagen type I N = 2.  For pDA with Collagen type IV N = 4.  For non-pDA PBS and 
non-pDA PBS + TGFβ EMT N = 2.  For all else N = 1. 
 
3.       Discussion 
3.1 Characterisation of NMuMGs Undergoing EMT Shows Genetic and Morphological 
Changes 
In this project study, a system using cryptic site signalling was designed to control the EMT 
in the application of fibrosis inhibition.  In the first project aim, the goal was to characterise 
EMT and β1LnLe1-4 protein influence in the NMuMG cell line, with the goal of using this 
system to study the PCL pDA membrane.  TGFβ-induced EMT in NMuMG cells was 
characterised by biochemical as well as molecular biological techniques, and observed 
morphological and gene expression changes corresponded strongly to EMT-like events.  
The morphological changes of EMT were apparent in light microscopy, as elongation and 
detachment of cells from rigid attachments were seen.  In immunofluorescence studies, 
cytoskeletal differences were observed in actin conformation, along with changes in 
morphology of fibronectin and collagen I.  Unfortunately, there was low immunofluorescent 
antibody signal for E-cadherin and N-cadherin, though both had signal in western blot 
analysis.  This phenomenon may be due to over-permeabilisation of the cell membranes 
during the fixing procedure, insufficient concentration of primary or secondary antibodies, 
rapid photo-bleaching during the experiment, and/or poor antibody specificity.  Ultimately 
with the view of focusing on fibrosis and EMT events, attempting to image the Cadherins by 
immunofluorescence was not pursued further in this study, but experiments currently 
ongoing indicate that the staining can be successful (data not shown).  In western blot 
analysis, Fibronectin was seen to be strongly up-regulated, with E-Cadherin and N-Cadherin 
EMT-switching not as readily apparent, but later elucidated by qPCR.  In qPCR studies, 
there is statistically significant E-cadherin down-regulation and up-regulation of MMP2, 
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MMP9, fibrogennectin – all corresponding to an EMT phenotype – along with clear up-
regulation trends for other genes.  The differences between TGFβ1 and TGFβ3 induced 
EMT were not significantly noticeable, and indeed the two isoforms, though appearing in 
different stages of development and in different tissues, compete for the same type I and 
type II receptors with approximately equal affinity, suggesting high similarity in activation 
strength and phenotype.62  In vivo, it is thought that TGFβ3 has a role in cell migration during 
wound healing, while TGFβ1 is also secreted by damaged cells during wound healing to 
contribute to the inflammatory and repair response.57,63  
The fragment β1LnLe1-4 influence was tested in this initial characterization system and 
showed many interesting trends.  In immunofluorescence studies, Fibronectin and Collagen I 
appeared qualitatively different with fragment-medium supplemented wells after TGFβ1 EMT 
compared to control wells, but such a phenomenon could be due to staining artefacts, and it 
may be difficult to infer whether there was actual up or down-regulation.  For qPCR studies 
of soluble laminin fragment there were potential trends in MMP2, TGFβ1, 2, 3 and 
EMMPRIN.  When fragment was introduced as a soluble factor, it is possible that fragment 
concentration was too low for significant binding to occur in rapidly dividing NMuMG cells.  
Over time, as concentration of fragment from solution does not increase, and may possibly 
decrease due to binding, uptake, and degradation events, the population of cells continued 
to increase quite rapidly, thus potentially diluting the number of cells that have bound 
fragment.  When fragment was coated onto the bottom of the tissue culture plastic, the 
increased fragment contact and possible availability of more cell binding sites noticeably 
altered qPCR mRNA expression.  There appeared to be stronger trends towards down-
regulation of MMP2, collagen type I, TGFβ3, TGFβ2, and EMMPRIN expression, suggesting 
that multiple complex EMT pathways including these proteins are involved.  The rapidly 
dividing nature of NMuMG cells with complex EMT dynamics contributed to high variation of 
fold-change in gene expression across different experiments.  This initial characterisation 
gave insight into how EMT genes are affected both undergoing TGFβ1 or TGFβ3-induced 
EMT and the influence of β1LnLe1-4 fragment.  Trends show similar response to mouse 
ESCs in monolayer culture (Figure 1D) in effectively down-regulating a variety of EMT 
genes.16  In conclusion, NMuMGs are a robust system for studying EMT and it appears that 
β1LnLe1-4 fragment does down-regulate critical EMT genes, including MMP2, as seen from 
previous studies with mESCs and hESCs. 
3.2 The Biomimetic Material Affects EMT-Related Genes in NMuMGs 
In the second project aim, a material system was optimized and characterized for stable 
protein binding.  In the biomimetic material system, the polydopamine coating method of 
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immobilising functional peptides on pDA PCL was used specifically to engineer an artificial 
basement membrane that can influence EMT.  Protein binding assays and immunostaining 
show that proteins such as collagen I, laminin-111, and laminin fragment are stably 
incorporated onto the surface of pDA PCL.  While it is observed that there is higher protein 
binding IR signal in non-pDA coated PCL, it is thought that this increased signal may be an 
artefact due to interference by the aromatic groups in pDA or due to altered surface 
properties from the coating.  As discussed previously, pDA coating is still desired for stable 
peptide binding and cell-seeding, especially because it guarantees a homogeneous and tight 
protein coating, which cannot be achieved on unprocessed PCL fibres.61  The binding 
characterisation of fluorescently labelled β1LnLe1-4 by confocal and TIRF imaging shows 
direct incorporation of the peptide onto the surface, demonstrating that the system can 
present specific proteins to cells that are cultured on the material.   
In the third aim, NMuMG cells were seeded on the material and their EMT behavior with and 
without β1LnLe1-4 fragment was studied.  Experiments for qPCR show high variability on 
the material due to the sensitivity of cells to the topology of the PCL surface, which can vary 
across different batches of PCL, as well as the cell-material well chamber system that 
demands lower cell densities, increasing the presence of heterogenic artefacts (Figure 14).  
In PCL mats without polydopamine coating there is curiously different behaviour from both 
control PBS and EMT-induced conditions compared to similar conditions with pDA (Figure 
13).  One possibility is that non-pDA PCL mats do not stably bind the β1LnLe1-4 protein.  
Additionally, it is possible that without pDA coating the adhesion properties of NMuMG on 
these surfaces are considerably different from PCL with pDA coating, which would effect 
EMT gene expression levels.   
The most potentially important result in the qPCR studies, however, is that there is a 
consistent decrease in MMP2 expression of cells undergoing EMT on the β1LnLe1-4 
fragment as soluble factor, coated on TCP, and coated on PCL, pDA, as MMP2 has been 
implicated as a major factor of fibrosis.30,64  While large variation and multiple-hypothesis 
correction leads to non-statistical significance, a more focused study specifically on MMP2, 
both with regards to gene expression and gene product levels, should clarify the result. 
There is also a definite trend of down-regulation on PCL pDA materials coated with both the 
fragment and collagen IV.  One possibility is that the collagens may cover the bioactivity of 
laminin fragment due to steric effects.  Notably, Collagen IV itself appears to have bioactivity 
in influencing EMT, noticeably up-regulating MMP2, collagen I, and fibronectin in non-EMT 
conditions.  As it is a critical part of the basement membrane, Collagen IV’s multi-
functionality is not surprising.  This trend may indicate that collagen IV is providing 
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biochemical and mechanical cues for NMuMGs on the PCL pDA coated material that may be 
inducing signalling events that are independent of TGFβ-induced EMT.  If this EMT gene up-
regulation activity by collagen IV was treated as independent from TGFβ EMT influence on 
genes, there would be a much stronger level of down-regulation of EMT genes for collagen 
IV and collagen IV with fragment samples (data not shown).  However, it is highly unlikely 
that the two inputs are independent, and therefore it is uncertain how much influence each 
factor is contributing.  The study of collagen IV and its possible cryptic and bioactive sites 
remains a fascinating area to be explored. 
 
4.       Conclusions 
4.1 Further Optimizing the Biomimetic System 
In this study, an artificial basement membrane was created in vitro that regulates EMT and 
fibrosis-related genes.  Further experiments need to be performed to optimise and 
characterise the material and cells in vitro so that the system can progress to animal model 
studies of wound healing fibrosis.  A wider range of EMT-related genes for cells on pDA PCL 
– including slug, snail, MMP9 – should be studied using qPCR.  Additionally, since many 
MMPs are secreted as zymogens that require activation, it will be useful to conduct 
zymography to complement the qPCR results.24 Zymography samples from cell-seeded PCL 
have been prepared to study MMP2 activity.  The challenge in this characterisation is due to 
the low populations of cells in each well, which makes activity of MMP2 difficult to detect 
even after concentrating media proteins.   
The stiffness, topology, and protein stability of PCL pDA mats will need to be more carefully 
characterised in potential animal models.  Studies have shown that epithelial cells have 
varying motility and ability to form epithelial sheets depending on the characteristics of their 
base substrates.47,65 It has been shown that matrix elasticity can direct lineage specification, 
which can be critically important in the EMT and wound healing.66,67  PCL stiffness should be 
tuned to the wound-healing application being studied, and other necessary functionalization 
either from additional peptides or through controlled changes in alignment and density of 
PCL fibres can be explored.48  Experiments optimizing the presentation of both collagen IV 
and laminin fragment may be performed to determine if there is a synergistic effect in down-
regulating EMT genes.  In the relatively simple coating system for this project, it appears that 
coating laminin fragment by itself remains the most effective artificial basement membrane 
system.  Further coating studies over longer time periods can determine the stability of 
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proteins on pDA and establish more quantitative binding kinetics properties for more 
predictable optimization and preparation of mats.  Additional characterisation of protein 
binding on pDA, zymography of MMP2, and qPCRs for additional EMT genes are currently 
underway. 
4.2 Applications to Fibrotic Disease: 
In this in vitro study, it was observed that EMT and fibrotic genes were down-regulated in 
qPCR studies.  To investigate the impact of down-regulating critical EMT genes in reducing 
fibrosis, animal models of fibrotic tissue will need to be studied using a variety of 
characterisation techniques to probe tissue stiffness, the presence of myofibroblasts, 
abundance of proteins as collagen I, and levels of pro-fibrotic growth factors.29,34,68,69  A 
model fibrotic wound healing system would typically be pulmonary, hepatic, or renal fibrosis 
pathologies that are found to be perpetuated by the EMT and in which the artificial basement 
membrane can serve as a bioactive scaffold and signaller.32,33,70,71  Once the pDA PCL 
system has been characterised and optimised in vitro from the work that is being currently 
performed, future efforts in making the system medically relevant will require these animal 
studies.  Early characterisations of polydopamine has shown low toxicity and immune 
response and may even reduce toxicity of other biomaterials.72,73  Additionally, recent 
advancements in organ-on-chip systems may provide opportunity in studying fibrotic models 
with human kidney or liver tissue through control of base material, cell patterning, and 
nutrient flow.74  In a recent study, a renal fibrosis EMT model had been built in a microfluidic 
chip.75  Unfortunately, due to the relative novelty of such systems, no robust fibrotic models 
are currently known, so the most likely clinical translation path still lies in in vivo animal 
models. 
4.3 Future Directions 
The biologically active laminin fragment and other similar down-regulators of EMT have 
potential applications beyond wound healing, especially in cancer metastasis.  In malignant 
cells, EMT may induce an auto-feedback loop by up-regulation of MMP-9 to cleave latent 
TGFβ, which would further increase expression and activation of EMT genes for cancer 
motility and transformation.76  In murine breast cancer cells EMT induces up-regulated 
expression of pro-angiogenic factor vascular endothelial growth factor (VEGF) and thus 
increases tumor angiogenesis and viability.77  In human hepatocellular carcinoma cells EMT 
activity has been implicated in angiogenesis and invasiveness, with down-regulation of EMT 
genes such as MMP2 reducing these tumorigenic events.78  Preliminary characterisation of 
β1LnLe1-4 protein effects on human breast cancer cells is underway.  Coupling EMT 
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regulators to artificial basement membrane systems such as pDA PCL will enhance localised 
delivery and optimal presentation of these signallers to cell receptors, thus potentially 
increasing the efficacy of the overall treatment.  As further understanding of the mechanisms 
of EMT and its input signals come to light, along with the development of robust 
biomaterials, the field of biological tissue engineering can begin to deliver local, effective, 
and patient-specific treatment for a variety of EMT-related pathologies.  
 
5. Materials and Methods 
5.1 Cell Culture 
 5.1.1 Cell Handling 
NMuMG cells (ATCC CRL-1636) were maintained in Dulbecco’s Modified Eagle Medium 
(DMEM; Life Technologies) with 10% (v/v) foetal bovine serum (FBS; Life Technologies), 
10μg/ml insulin (Sigma), and 100U/mL penicillin-streptomycin (Life Technologies) at 37oC 
and 5% CO2 grown on tissue culture plastic (TCP).  Cells were detached with 0.05% (v/v) 
1X trypsin-EDTA (Life Technologies) and passaged at 80% confluency (2-3 days).  For 
cryopreservation, the growth medium is supplemented with 5% (v/v) DMSO (Sigma) and 
gradually frozen down and stored in liquid nitrogen. 
5.1.2 EMT Induction and Fragment Addition 
To induce EMT, TGFβ1 (Sigma) or TGFβ3 (Sigma) was added to cells at 80-90% confluency 
at a concentration of 10ng/ml in cell medium.  Fragment not on PCL material was added in 
two different methods.  For soluble fragment, cell medium was complemented with soluble 
recombinant β1LnLe1-4 at concentration at 10μM in PBS and added at time of initial cell 
seeding on TCP.  For coated fragment, 6-well TCPs were coated with laminin β1LnLe1-4 
fragment by incubating with 10μM fragment in PBS for 4 hrs at 37oC.   
5.1.3 Recombinant β1LnLe1-4 Fragment Production 
Recombinant laminin-111 fragment β1-LnLe1-4 was produced and purified according to 
previously published methods.55 The β1-LnLe1-4 sequence was inserted into a pCEP-Pu 
vector coding with a C-terminal His6-tag. Transfected human embryonic kidney HEK293 c18 
cells (ATCC CRL-1573) were used for protein production and cultured at 37oC and 5% CO2.  
The culture medium has the composition: Dulbecco’s modified Eagle’s medium/nutrient 
mixture F-12 (Invitrogen) containing 10% (v/v) foetal bovine serum (FBS; Life Technologies), 
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2 mM glutamine, 10 units/ml penicillin, 100 μg/ml streptomycin, and 250 μg/ml Geneticin (all 
from Gibco).  Transfection was performed using FuGENE 6 (Roche Diagnostics) and 
selected with 1 μg/ml puromycin (Sigma). Transfected cells were grown to confluence in 
HYPERFlask vessels (Corning), washed with PBS, and incubated with serum-free medium 
for 3 weeks with weekly medium changes. The laminin- 111 fragment was purified from 
serum-free conditioned medium by nickel affinity chromatography using 5 ml HisTrap FF 
columns (GE Healthcare) and an ÄKTA FPLC system (GE Healthcare). The purified protein 
was concentrated to 1 mg/ml using Amicon ultracentrifugal 10K MWCO units (Fisher 
Scientific UK), analyzed by SDS-PAGE, and stored at -20°C.  All steps were performed by 
Christine-Maria Horejs.  
5.2 qPCR: 
5.2.1 Cell Sample Preparation 
For standard plate culturing, cells were harvested as described before and lysed in 350μL 
RLT buffer (Qiagen).  For cells on PCL mats, the mat itself was placed into 350μL RLT 
buffer solution and vigorously vortexed.   
5.2.2 RNA Extraction and Purification 
RNA was isolated using the RNeasy Mini Kit (Qiagen) according to manufacturer’s standard 
protocol for each sample as follows: 1) Lysate is pipetted into a QIAshredder spin column 
placed in a 2 mL collection tube and centrifuged for 2 min at full speed.  2) 350μL 70% 
ethanol is added to the homogenised lysate and mixed will by pipetting.  3) The 700μL 
sample is transferred to an RNeasy spin column placed in a 2mL collection tube and 
centrifuged for 15s at 10,000rpm in a centrifuge (Eppendorf Microcentrifuge 5424).  4) The 
flow-through is discarded and 700μL RW1 buffer is added to the spin column. The column is 
centrifuged again for 15s at 10,000rpm and the flow-through discarded.  5) 500μL RPE 
buffer is then added.  The column is centrifuged for 15s at 10,000rpm and flow through 
discarded.  6) The previous step is repeated once again before the RNEasy spin column is 
placed in a new 2mL collection tube and centrifuged at full speed for 1 min.  The RNeasy 
spin column is then placed in a new collection tube.  7) 30μL RNase-free water is added to 
the spin column membrane and the column is centrifuged for 1 min at 10,000 rpm to elute 
the RNA.   
5.2.3 Reverse Transcription 
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Reverse transcription into cDNA was performed using a QuantiTect Reverse Transcription 
Kit (Qiagen) according to manufacturer’s standard protocol for each sample as follows: 1) 
The concentration of RNA is determined using Nanodrop 2000 (Thermo Scientific) and is 
then diluted to 40ng/μL.  2) 12μL of RNA and 2μL of gDNA wipeout buffer are mixed in PCR-
tubes (Axygen) and incubated for 2 min at 42oC in a thermal cycler, then placed back on ice.  
3) The reverse-transcription master mix per sample is prepared with 1μL Quantiscript 
reverse transcriptase, 4 μL Quantiscript RT buffer, and 1μL RT primer mix.  4) This mixture 
is added to the RNA in the PCR tube to make a total of 20μL reaction volume.  5) In the 
thermal cycler, the tube is incubated for 15 min at 42oC and then 3 min at 95oC.  6) For long 
term storage, this complementary DNA (cDNA) mixture is stored at -20oC. 
5.2.4 qPCR of cDNA Samples 
QuantiTect SYBR Green PCR Kit (Qiagen) was used according to manufacturer’s protocol 
for each sample as follows: 1) cDNA samples prepared previously were diluted 1:10 in 
RNase free water.  2) Primers (see next section) at 10μM were mixed to1μL (forward + 
reverse) and added to 5μL SYBR green.  3) 4μL diluted cDNA and 6μL SYBR mix were 
mixed together in the final volume.  4) Thermocycling and SYBR green signal detection were 
both performed on a Corbett Rotorgene 6000 (Qiagen), with extension temperature at 72oC 
and denaturing temperature at 95oC.  The annealing temperatures of all primers were at 
55oC.  Each sample was run in duplicate and signal was averaged in the analysis. 
5.2.5 Primers: 
The following primers were used (Invitrogen unless specified): 
GAPDH: [Forward (For), 5’-TGGTATCGTGGAAGGACTCATGA-3’;  
Reverse (Rev), 5’-ATGCCAGTGAGCTTCCCGTTCAG-3’] 
MMP2: [For, 5′-ATGGCAAGTATGGCTTCTG-3′; 
Rev, 5′-GTAGGAGGTGCCCTGGAAG-3′] 
MMP9: [For, 5’-TGTACCGCTATGGTTACAC-3’; 
 Rev, 5’-CGGCGACACCAAACTGGAT-3’] 
E-cadherin: [For, 5′-CGAGAGAGTTACCCTACATA-3′; 
Rev, 5′-GTGTTGGGGGCATCATCATC-3′)]  
N-cadherin: [For, 5′-AGGGTGGACGTCATTGTAGC-3′; 
Rev, 5′-CTGTTGGGGTCTGTCAGGAT-3′] 
Slug: [For, 5′-ACATTAGAACTCACACTGGGGA-3′; 
Rev, 5′-GCAGAAGCGACATTCTGGAG-3′] 
Snail: [For, 5′-CATCCTTGGGGCGTGTAAGT-3′;  
Rev, 5′-ATGGCATGGGGGTCTGAAAG-3′]  
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Collagen Type I: [For, 5’-TAAGGGTCCCCAATGGTGAGA-3’; 
 Rev, 5’-GGGTCCCTCGACTCCTACAT-3’] 
TGFβ-1: [For, 5’-CCACCTGCAAGACCATCGAC-3’; 
 Rev, 5’-CTGGCGAGCCTTAGTTTGGAC-3’] 
TGFβ-2: [For, 5’-CTTCGACGTGACAGACGCT-3’; 
 Rev, 5’-GCAGGGGCAGTGTAAACTTATT-3’] 
TGFβ-3: [For, 5’-GGACTTCGGCCACATCAAGAA-3’; 
 Rev, 5’-TAGGGGACGTGGGTCATCAC-3’] 
EMMPRIN: [For, 5’-CCTGCATACGAAGTACATAGTGG -3’; 
 Rev, 5’-TGATTTCTTTCGGACCTTGATCC -3’] 
Integrin α3: [For, 5’-ACTGTGAACGGATGGACATTTC-3’; 
 Rev, 5’-ACAGACCAGGACTCTACCTGC-3’] 
Integrin β1: [For, 5’-ATGCAAATCTTGCGGAGAAT -3’; 
 Rev, 5’-TTTGCTGCGATTGGTGACATT-3’] 
Fibronectin 1: [For, 5’-CCCTATCTCTGATACCGTTGTCC-3’; 
Rev, 5’-TGCCGCAACTACTGTGATTCGG-3’]; (qSTAR primers from Origene) 
 
5.2.6 Analysis:  
Real-time PCR data was analysed by the comparative Ct method.79-81  In this method, the 
fold change is defined as 2−∆∆𝐶𝐶𝐶𝐶, where −∆∆𝐶𝐶𝐶𝐶 = [(𝐶𝐶𝐶𝐶 𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔 𝑜𝑜𝑜𝑜 𝑖𝑖𝑔𝑔𝐶𝐶𝑔𝑔𝑖𝑖𝑔𝑔𝑖𝑖𝐶𝐶 −
𝐶𝐶𝐶𝐶 𝑖𝑖𝑔𝑔𝐶𝐶𝑔𝑔𝑖𝑖𝑔𝑔𝑖𝑖𝑖𝑖 𝑐𝑐𝑜𝑜𝑔𝑔𝐶𝐶𝑖𝑖𝑜𝑜𝑖𝑖) 𝑣𝑣𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑣𝑣𝑖𝑖𝑔𝑔 𝑖𝑖𝑖𝑖𝑠𝑠𝑠𝑠𝑖𝑖𝑔𝑔 − (𝐶𝐶𝐶𝐶 𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔 𝑜𝑜𝑜𝑜 𝑖𝑖𝑔𝑔𝐶𝐶𝑔𝑔𝑖𝑖𝑔𝑔𝑖𝑖𝐶𝐶 −
𝐶𝐶𝐶𝐶 𝑖𝑖𝑔𝑔𝐶𝐶𝑔𝑔𝑖𝑖𝑔𝑔𝑖𝑖𝑖𝑖 𝑐𝑐𝑜𝑜𝑔𝑔𝐶𝐶𝑖𝑖𝑜𝑜𝑖𝑖) 𝑐𝑐𝑜𝑜𝑔𝑔𝐶𝐶𝑖𝑖𝑜𝑜𝑖𝑖 𝑖𝑖𝑖𝑖𝑠𝑠𝑠𝑠𝑖𝑖𝑔𝑔)].  Ct is defined as the cycle where signal crosses a set 
threshold (see appendix for thresholds).  The normalised control for NMuMG cells was the 
no fragment no EMT condition.  The normalised control for the material system for NMuMG 
cells was pDA PCL with PBS mats (no protein coating).  The internal control gene is 
GAPDH.  Data is shown as Log(fold change) so that down-regulation events are scaled 
equally to up-regulation events. For statistical significance of differences in expression 
between one EMT and one non-EMT condition across multiple genes, ANOVA test with 
Bonferroni correction was used.  For significance between a non-EMT condition and multiple 
EMT conditions for one gene Dunnett’s test was used.  Tests were performed using 
GraphPad Prism software. 
5.3 Western Blot 
Cells were lysed with RIPA buffer with protease inhibitors (Sigma).  Cell lysate samples were 
shaken vigorously and centrifuged at 4oC. The proteins were then separated by SDS-PAGE, 
transferred onto nitrocellulose membranes, and blocked with blocking buffer – 5% (w/v) milk 
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powder (Sigma) in TBST (20mM Tris-HCl, 136mM NaCl, 1% (v/v) Tween-20) –for 1 hr.  The 
membranes were incubated in primary antibodies in blocking buffer overnight at 4oC, and 
exposed to secondary antibodies in blocking buffer for one hr before being imaged and 
analysed using Odyssey LiCor Software (LiCor). 
5.4 Immunostaining 
NMuMG cells were fixed in 4% (v/v) paraformaldehyde for 20 min at room temperature.  
They were then permeabilised in 0.1% (v/v) Triton X-100 for 5 min and blocked with 3% 
(w/v) BSA solution for 1 hr at room temperature.  Samples were incubated in primary 
antibodies in BSA overnight and in secondary antibodies for 1 hr at room temperature.  
Confocal images were collected by a Zeiss LSM-510 inverted confocal microscope and 
processed using Fiji (ImageJ).  For all other fluorescence images an Evos FL Cell Imaging 
System (Life Technologies) was used. 
Primary antibodies: anti-GAPDH (1:200) (Santa-Cruz sc32233), anti-E-Cadherin (1:200) (BD 
610181), anti-N-Cadherin (1:200) (Santa-Cruz sc59987), anti-Fibronectin (1:500) (Abcam 
23750), anti-Collagen I (Abcam 34710), anti-Actin (1:100) (AlexaFluor 488 phalloidin), anti-
EMMPRIN (1:500) (ebioscience1601471082 and Abcam 70062). 
Secondary antibodies: Alexafluor series (1:1000) (555, 568, 488 goat anti-mouse) and LiCor 
IRDyes (1:1200) (680 and 800 goat anti-mouse, goat anti-rabbit) 
5.5 Polydopamine Coated Poly(ε-caprolactone) 
5.5.1 Electrospinning:  
Electrospinning of poly(ε-caprolactone) (PCL) membranes was performed according to 
previously described methods on a custom-made electrospinning setup.48  PCL with number 
average Mn molecular weight of 80,000 (Sigma) was dissolved in 1,1,1,3,3,3-
hexafluoroisopropanol (HFIP) at a concentration of 12% (w/v).  The solution was pushed 
through an 18-gauge blunt-tip needle at a flow rate of 2ml/hr.  A voltage of 16kV was applied 
to the needle and the fibres formed were collected onto a mandrel situated 11cm from the 
needle tip and rotating at a speed of 1m/s.  This procedure results in randomly aligned fibres 
that are approximately 1μm in diameter (Figure 2B).  
5.5.2 Polydopamine Coating 
Eight mm diameter circular mats were cut from the electrospun PCL sheet using a hollow 
punch (Boehm).  The mats were then air plasma-treated using a Plasma Prep 5 (Gala 
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Instrumente) at 50% power and 0.4mbar for 1 min to render them hydrophilic and ensure 
uniform pDA coating.82  Dopamine hydrochloride (Sigma) was dissolved at 2mg/mL in 
~20mL of 10mM Tris with pH 8.5.51  The Tris solution was prepared using Tris-base (Sigma) 
and titrated with HCl and NaOH using a pH meter.  The PCL mats were stirred in the 
polydopamine solution for 4 hrs in an opened vial.  The mats are then washed overnight with 
distilled water changed approximately four times until no pDA release is observed. 
5.5.3 IR Protein Binding Assay  
Polydopamine coated PCL disks were prepared as described above, air-dried and weighed.  
Collagen I solution was prepared by diluting rat tail collagen I (BD) to 100µg/mL in PBS or 
10mM pH 8.5 Tris. The disks were incubated in 200μL of collagen type I solution for 24 hrs.  
Each plate was sealed thoroughly to prevent evaporation.  The disks were blocked in 
1μg/mL BSA solution, incubated in anti-collagen I antibody (see above) for 2 hrs followed by 
the secondary antibodies (IR 800) for 1 hr, then imaged and analysed using Odyssey LiCor 
Software (LiCor).  Each sample was run in triplicate and infrared signal quantified and 
normalised to dry mass. 
5.5.4 BCA Protein Assay 
Samples of pDA PCL disks were incubated in 200μL of 100μg/mL laminin-111 (Sigma) 
diluted in PBS for time periods of 5, 15, 30, 60, 120 min, 6 hrs, and 24 hrs in 48-well plates 
(Corning).  A standard concentration curve from 0 to 100μg/mL was also prepared from the 
laminin-111 (without PCL).  BCA protein assay kit (Pierce) was used according to 
manufacturer’s protocol (Pierce) as follows:  For each sample 200μL BCA reagent mix – 50 
parts BCA reagent A to 1 part BCA reagent B – was added.  The samples were incubated at 
60oC for 30 minutes and then cooled down and read on a spectrophotometer plate reader.  
The signal was normalised to non-incubated control wells and the concentration of protein 
remaining in the well was derived from fitting to the concentration curve.   
5.5.5 Protein Coating for Cell-Seeding:  
The PCL pDA mats were sterilised by placing them for 30 min in 70% (v/v) EtOH-distilled 
water solution.  All subsequent steps were performed in a cell hood under sterile conditions 
and reagents. The mats were washed three times with phosphate-buffered saline (PBS; Life 
Technologies) and put into a 48-well plate (Corning).  Laminin fragment in PBS at 9μg/ml 
was added and the mats were incubated at 37oC for 8 hrs.  Subsequently, the mats were 
washed three times again with PBS.  Rat tail collagen type I in acetic acid (BD) or collagen 
type IV in HCl (BD) diluted to 100 μg/ml or 10 μg/ml respectively in PBS was added to the 
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appropriate wells and the plate was incubated for 16 hrs, followed by washing the mats three 
times with PBS. 
5.5.6 Preparation of PCL Cell Chambers:  
Cell chambers were made from domed 8-cap and tube strips for PCR (Axygen).  Using a 
razor blade, the top dome part of the caps was cut off and the remaining caps were 
separated from each other.  The tubes were cut such that the bottom cone was separated 
from the top.  The top of the tubes and the cut caps can then sandwich a PCL mat, holding it 
in place, while creating a small chamber for cell media to be put on top.  Figure 14 illustrates 
the configuration.  PCL cell chambers (caps and tube tops) were sterilised in 70% (v/v) EtOH 
and rinsed several times with PBS.  Each tube top and cap were put together with a pDA-
coated PCL mat in between and placed in a 24-well plate (Corning).  The final assembly was 
rinsed twice with PBS and once with cell medium.  All liquid was then aspirated off and 
200μL media was dispensed in each well (but not inside the chamber caps) and placed in an 
incubator in preparation for cell seeding. 
5.6 Cell Handling on PCL Mats 
5.6.1 Cell Seeding on PCL 
Cells were harvested as described previously and counted using a haemocytometer.  They 
were then diluted to the concentration of 12,000 cells / 50μL.  50μL of cell solution was then 
gently pipetted into each cell chamber on top of the PCL mat.  Cells were then allowed to 
settle for 5 to 10 min, and then 550μL of media was carefully pipetted into each well so that 
the cell chamber does not leak dry.  The plate was then incubated as described previously. 
5.6.2 EMT Induction on PCL 
All media was carefully aspirated from each well, and 1mL of media complemented with 
concentration of 10ng/μL TGFβ1 was added into each well.  For control samples medium 
without TGFβ was added. 
5.7 Imaging 
5.7.1 Light Imaging 
Light microscopy images were collected on an IX51 inverted microscope (Olympus) 
5.7.2 TIRF and Confocal Imaging Sample Preparation 
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Cell-seeded pDA PCL mats were fixed in the same manner described previously while still in 
the cell chambers.  After cells were fixed and washed, the mats were taken out of the 
chambers.  The cells were permeabilised in 0.1% (v/v) Triton for 5 min and then blocked for 
45 min with 3% (w/v) BSA in PBS.  Antibody application and imaging were subsequently 
performed by Christine-Maria Horejs and Thomas von Erlach.  TIRF imaging was performed 
on a Zeiss Axiovert 200 manual inverted microscope with a 488 laser diode, 100X/1.45W 
alpha Plan-Fluar objective, and back illuminated EM-CCD camera (Hamamatsu C9100-13).  
Confocal imaging was performed on a SP5 Leica laser-scanning confocal fluorescence 
microscope with HC PL APO 10x 0.40 CS air objective. 
 
Figure 14 | Construction of Cell Chamber 
A, PCR strip-tubes and caps are cut along the red lines to yield the bottom of the caps and the top of 
the tubes. B, The PCL mat is sandwiched between the tube-top and cap-bottom.  The configuration is 
placed in a 24-well plate to create a cell chamber.  The outside of the chamber is filled with media to 
prevent leakage and drying out of the cells. 
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7. Appendix 
 
7.1 List of Abbreviations 
 
Acronym Meaning 
BM Basement Membrane 
cDNA 
Complementary 
Deoxyribonucleic Acid 
DMEM 
Dulbecco's Modified 
Eagle Medium 
ECM Extracellular Matrix 
EMMPRIN 
Extracellular Matrix 
Metalloproteinase 
Inducer 
EMT 
Epithelial-to-
Mesenchymal 
Transition 
EndoMT 
Endothelial-to-
Mesenchymal 
Transition 
ESC Embryonic Stem Cell 
FBS Foetal Bovine Serum 
HFIP 
1,1,1,3,3,3-
Hexafluoroisopropanol 
IR Infrared 
LC-MS 
Liquid 
Chromatography 
Tandem Mass 
Spectrometry 
LE 
Laminin-type 
Epidermal Growth 
Factor-like  
LG Laminin Globular  
LN Laminin N-terminal  
MMP 
Matrix 
Metalloproteinase  
MMS 
Molecular Mass 
Standard 
NMuMG 
Mus Musculus 
Mammary Gland 
Epithelial Cells 
PA Plasma Air 
PCL Poly(ε-caprolactone)  
pDA Polydopamine 
qPCR 
Quantitative 
Polymerase Chain 
Reaction 
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SEM 
Scanning Electron 
Microscope/ Standard 
Error of Mean 
TCP Tissue Culture Plastic 
TGFβ 
Transforming Growth 
Factor β  
TIRF 
Total Internal 
Reflection 
Fluorescence 
VEGF 
Vascular Endothelial 
Growth Factor 
 
7.2 RT-PCR primer threshold validations 
For threshold calculations, primers were added to cDNA of NMuMG non-EMT 
samples diluted 1:10, 1:100, 1:1000, and fluorescence was measured according to 
the qPCR procedure described previously.  Threshold value was determined as the 
normalised fluorescence that gives threshold cycle (CT) values resulting in a linear 
curve that maximizes fit for the dilutions in log-space.  Each dilution has n = 3, with 
curves that are closely clustered together. 
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